Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion

Cancer Investigation

Volumn 29, Issue 8, 2011, Pages 501-510

  Song, Guang Yun ^a   Srivastava, Tumul ^a   Ishizaki, Hidenobu ^a   Lacey, Simon F ^a   Diamond, Don J ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cancer patients; CTL expansion; MVA; P53; PBMC; Peptide library

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; MODIFIED VACCINIA VIRUS ANKARA; PROTEIN P53; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CELL DEGRANULATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 80052782571     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.606248     Document Type: Article

References (49)

1. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Mun-shi N, Avigan D. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011;117:393-402.
2. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 2010;59:1211-1221.
3. Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. BTLA mediates inhibition of human tumor-specifc CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010;120:157-167.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
5. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993;7:855-865. (Pubitemid 23225541)
6. Teobald M, Ofringa R. Anti-p53-directed immunotherapy of malignant disease. Expert Rev Mol Med 2003;5:1-13.
7. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010;2:a001222.
8. Mayordomo JI, Lofus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Terapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-1365.
9. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI. An efective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ter 2002;9:345-352. (Pubitemid 34285148)
10. DeLeo AB, Whiteside TL. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 2008;7:1031-1040.
11. Dafarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 2004;64:5407-5414. (Pubitemid 39006563)
12. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003;170:3401-3407. (Pubitemid 36302220)
13. Ishizaki H, Song GY, Srivastava T, Carroll KD, Shahabi V, Manuel ER, Diamond DJ, Ellenhorn JD. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother 2010;33:609-617.
14. Song GY, Gibson G, Haq W, Huang EC, Srivasta T, Hollstein M, Dafarian P, Wang Z, Diamond D, Ellenhorn JD. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 2007;56:1193-1205. (Pubitemid 46763934)
15. Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin Immunol 2007;125:43-51. (Pubitemid 47374535)
16. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, DeLeo AB. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-1288. (Pubitemid 29282930)
17. Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T. 2005. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efciently induce CTLs against p53 overexpressing human cancer cells. Clin Cancer Res 2005;11:1312-1318. (Pubitemid 40175785)
18. Wurtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002;99:568-572. (Pubitemid 34461610)
19. Teobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-11997. (Pubitemid 26013997)
20. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfout JW, van de Velde CJ, Melief CJ, van der Burg SH. Induction of p53-specifc immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009;15:1086-1095.
21. van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Of-fringa R, Melief CJ. Induction of p53-specifc immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 2002;8:1019-1027. (Pubitemid 34517635)
22. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus AD. Safety of modifed vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001;19:3700-3709. (Pubitemid 32522768)
23. Tartaglia J, Pincus S, Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol 1990;10:13-30. (Pubitemid 20074273)
24. Antoine G, Scheifinger F, Dorner F, Falkner FG. Te complete genomic sequence of the modifed vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998;244:365-396. (Pubitemid 28384101)
25. La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sha-ran R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002;100:3681-3689. (Pubitemid 35303939)
26. Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011;239:8-26.
27. Tykodi SS, Tompson JA. Development of modifed vaccinia Ankara-5T4 as specifc immunotherapy for advanced human cancer. Expert Opin Biol Ter 2008;8:1947-1953.
28. Elkord E, Dangoor A, Drury NL, Harrop R, Burt DJ, Drijfout JW, Hamer C, Andrews D, Naylor S, Sherlock D, Hawkins RE, Stern PL. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 2008;31:820-829.
29. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A. Vaccination of colorectal cancer patients with modifed vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13:4487-4494. (Pubitemid 47219718)
30. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modifed vaccinia virus (MVA) expressing human MUC1 as antigen-specifc immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5:690-699. (Pubitemid 40309707)
31. Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Turner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wolfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modifed vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005;54:453-467. (Pubitemid 40543685)
32. Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother 2010;33:999-1005.
33. Mandl SJ, Delcayre A, Curry D, Dal Pazzo K, Fernandez L, Njoku T, Riggs R, Treiger B, Laus R. MVA-BN-HER2: a novel vaccine for the treatment of breast cancers which overexpress HER-2. J Immunother 2006;29:652.
34. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, Krzakowski M, Hess D, Tartour E, Chenard MP, Limacher JM, Bizouarne N, Acres B, Halluard C, Velu T. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Torac Oncol 2008;3: 735-744.
35. Amato RJ. 5T4-modifed vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ter 2010;10:281-287.
36. Erbs P, Findeli A, Kintz J, Cordier P, Hofmann C, Geist M, Balloul JM. Modifed vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ter 2008;15:18-28. (Pubitemid 350261298)
37. Hernandez J, Lee PP, Davis MM, Sherman LA. Te use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000;164: 596-602. (Pubitemid 30043678)
38. Lefers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oosten-dorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Immunization with a P53 synthetic long peptide vaccine induces P53-specifc immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009;125:2104-2113.
39. Lambeck A, Lefers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfout JW, Platteel I, Ofringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. P53-specifc T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer 2007;121:606-614. (Pubitemid 46986494)
40. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Ofringa R, Melief CJ. Antitumor ef-cacy of wild-type p53-specifc CD4(+) T-helper cells. Cancer Res 2002;62:6187-6193. (Pubitemid 35244470)
41. Andrade Filho PA, Ito D, Deleo AB, Ferris RL. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2010;59:1561-1568.
42. Antonia SJ, Mirza N, Fricke I, Chiappori A, Tompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-887. (Pubitemid 43259871)
43. Ren SP, Wu CT, Huang WR, Lu ZZ, Jia XX, Wang L, Lao MF, Wang LS. Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autol-ogous anti-tumor cytotoxicity of multiple myeloma cells in vitro. Cancer Immunol Immunother 2006;55:375-385. (Pubitemid 43076889)
44. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8 +cytotoxic T-cells. Cancer Res 1993;53:3257-3261. (Pubitemid 23223293)
45. Wurtzen PA, Pedersen LO, Poulsen HS, Claesson MH. Spe-cifc killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specifc CTL line. Int J Cancer 2001;93:855-861. (Pubitemid 32761693)
46. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tan-imura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001;84:1052-1057. (Pubitemid 32448501)
47. Hofmann TK, Lofus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB. Te ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53 (264-272) epitope. J Immunol 2002;168:1338-1347. (Pubitemid 34094504)
48. Menon AG, Kuppen PJ, van der Burg SH, Ofringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ter 2003;10:509-517. (Pubitemid 36842008)
49. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Hes-lop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic-T-lymphocytes specifc for a new preferentially expressed antigen of melanoma (PRAME)-derived pep-tide can target leukemic-and leukemic-precursor cells. Blood 2011;117:3353-3362.